# breast cancer - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 7
- Task type: PROGNOSIS
- Tissue / sample source: breast tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: 2eef237c25053f55d87c73e963368cae88b5c698447f11e7e98ebc594d62e5bb
- Response HTTP status: 200
- Prompt tokens: 3922
- Completion tokens: 24176
- Reasoning tokens: 
- Total tokens: 28098
- API requests reported: 
- Elapsed seconds: 246.772
- Final benchmark system: raw; file rank 5/5; original repeat 7; model vendor: DeepSeek

---
Important: the statistical input is a Cox regression table. HR > 1 means higher expression of that gene is associated with worse overall survival (“risk-associated”); HR < 1 means higher expression is associated with better overall survival (“protective-associated”). Because the tissue is bulk breast tumor, these associations include contributions from tumor cells, immune cells, stromal cells, and other microenvironmental components. The interpretation below is therefore a biological synthesis, not a causal proof.

## 1. Overall biological interpretation

The prognostic transcriptome separates into two broad, opposing biological axes.

- **Poor-survival / risk arm:** dominated by genes involved in **cell-cycle progression, mitosis, chromosome segregation, DNA replication, RNA processing/translation, and ubiquitin-proteasome proteostasis**. These genes point to highly proliferative tumor cells with elevated biosynthetic and protein-turnover demands.
- **Good-survival / protective arm:** dominated by genes marking **immune cell infiltration, particularly dendritic cells, plasma cells, and NK/T-cell-associated transcripts**, as well as **extracellular matrix / stromal / differentiation-associated genes**. This arm suggests that a non-proliferative, differentiated tumor phenotype and/or a supportive anti-tumor immune microenvironment are associated with better overall survival.

This risk/protective pattern is biologically coherent in breast cancer: proliferation is a classic adverse prognostic feature, whereas immune infiltration and stromal/differentiation features often associate with more favorable outcomes, although the latter is likely partly cell-composition driven.

## 2. Core biological programs

### Program 1: Cell cycle, mitosis, and chromosome segregation  
**Direction:** Risk-associated  

**Major supporting genes:**  
AURKA, TPX2, CDC20, UBE2C, UBE2S, PTTG1, PRC1, KIF20A, KIF4A, RACGAP1, NUSAP1, CKAP2L, CENPO, ZWINT, CDCA5, CCNE2, TK1, TIMELESS, FEN1, PKMYT1  

**Standard pathway:**  
KEGG cell cycle; Reactome cell cycle / mitotic; Hallmark G2M checkpoint / E2F targets  

**Why this is a coherent program:**  
These genes represent multiple independent layers of proliferation: centrosome maturation and spindle assembly (AURKA, TPX2), kinetochore–microtubule attachment (ZWINT, CENPO), APC/C-mediated mitotic exit (CDC20, UBE2C, UBE2S, PTTG1), cytokinesis (PRC1, KIF4A, RACGAP1, KIF20A), and DNA replication (TK1, FEN1, TIMELESS, CCNE2). Their consistent risk direction makes this the strongest signal in the table.

**Strength and limitations:**  
Strong: many genes, very low FDRs, and a well-defined shared biology. Limitation: bulk expression of these genes may simply reflect tumor cell proliferation, grade, or subtype, rather than a specific causal driver.

---

### Program 2: RNA metabolism, ribosome biogenesis, and translational control  
**Direction:** Risk-associated  

**Major supporting genes:**  
LARP1, UTP23, DDX41, YTHDF1  

**Standard pathway:**  
GO: ribosome biogenesis; Reactome translation / rRNA processing  

**Why this is a coherent program:**  
LARP1 is a mTORC1-regulated RNA-binding protein that controls translation of ribosomal protein mRNAs; UTP23 and DDX41 are involved in ribosomal RNA processing; YTHDF1 promotes translation of m6A-modified mRNAs. Together they point to increased protein synthesis capacity supporting tumor growth.

**Strength and limitations:**  
Moderate: fewer genes than the mitotic program, but they converge on a common biological process. Limitation: DDX41 also has innate immune functions, and increased translation may be a general consequence of proliferation rather than an independent driver.

---

### Program 3: Ubiquitin–proteasome system and protein homeostasis  
**Direction:** Risk-associated  

**Major supporting genes:**  
STIP1, PSMD3, UBE2C, UBE2S, USP30, FAF2, ZFP91, RMND5B  

**Standard pathway:**  
KEGG proteasome; Reactome ubiquitin-dependent degradation  

**Why this is a coherent program:**  
STIP1 is a co-chaperone for Hsp70/Hsp90; PSMD3 is a 19S proteasome subunit; UBE2C and UBE2S are ubiquitin-conjugating enzymes; USP30 is a deubiquitinase; FAF2 is involved in ER-associated degradation. This cluster indicates elevated protein turnover and proteotoxic stress management, which are common features of aggressive tumors.

**Strength and limitations:**  
Moderate. Limitation: UBE2C and UBE2S also participate in mitotic APC/C function, so this program partially overlaps with Program 1; proteasome gene expression can be a generic growth/stress response.

---

### Program 4: Immune infiltration and antigen presentation  
**Direction:** Protective-associated  

**Major supporting genes:**  
FCER1A, CD1C, CD1E, JCHAIN, KLRB1, IL27RA, FLT3, STAT5A, STAT5B  

**Standard pathway:**  
Reactome immune system; GO antigen processing and presentation  

**Why this is a coherent program:**  
FCER1A and CD1C/CD1E are dendritic-cell-associated markers; JCHAIN marks antibody-secreting plasma cells; KLRB1 marks NK/T-cell subsets; IL27RA is involved in immune regulation; FLT3 is expressed on dendritic cell progenitors; STAT5A/B contribute to immune and differentiation signaling. The collective protective direction strongly suggests that immune infiltration, especially dendritic and lymphoid components, is associated with better overall survival.

**Strength and limitations:**  
Strong because multiple independent immune-lineage markers share the same protective direction. Limitation: this is likely a cell-composition signal in bulk tissue rather than purely a tumor-cell-intrinsic phenotype.

---

### Program 5: Extracellular matrix, stromal microenvironment, and differentiation  
**Direction:** Protective-associated  

**Major supporting genes:**  
OGN, OMD, MFAP4, LAMA2, COL14A1, COL17A1, CLDN11, ADAMTS8, RELN, PDGFRA, LEPR, TP63, SPRY2, CDKN2C, RBBP8, CBX7  

**Standard pathway:**  
Reactome extracellular matrix organization; GO extracellular matrix  

**Why this is a coherent program:**  
Many protective genes encode ECM structural proteins, proteoglycans, basement-membrane components, and matrix-remodeling enzymes. Others, such as TP63, SPRY2, CDKN2C, and RBBP8, are associated with epithelial differentiation, growth arrest, or tumor-suppressive signaling. This suggests that a differentiated tumor phenotype and/or a stromal microenvironment that restrains progression are associated with better survival.

**Strength and limitations:**  
Broad gene support, but this is the least specific program. Limitation: it probably mixes multiple cell types and pathways; some genes, such as CCND2 and ABCB1, have context-dependent roles and do not fit a simple “differentiation” label.

---

## 3. Key genes and interaction modules

### 1. AURKA / TPX2 module  
- **Direction:** Both risk-associated.  
- **Role:** Centrosome maturation, mitotic spindle assembly, mitotic entry.  
- **Gene-gene relationship:** Direct physical interaction established in cell biology: TPX2 binds AURKA and activates it. The current dataset shows only co-risk expression, not direct interaction.

### 2. APC/C ubiquitination module: CDC20 / UBE2C / UBE2S / PTTG1  
- **Direction:** All risk-associated.  
- **Role:** APC/C-mediated ubiquitination of securin and cyclins to drive anaphase and mitotic exit.  
- **Gene-gene relationship:** Functional complex / pathway co-membership. CDC20 directly activates APC/C; UBE2C and UBE2S are E2 enzymes; PTTG1 is an APC/C substrate. Pairwise direct interactions are not all established from this dataset.

### 3. Cytokinesis / central spindle module: PRC1 / KIF4A / RACGAP1 / KIF20A  
- **Direction:** All risk-associated.  
- **Role:** Microtubule bundling at the midzone and cleavage furrow regulation.  
- **Gene-gene relationship:** PRC1 and KIF4A have a known direct physical interaction. RACGAP1 and KIF20A are best described as pathway co-members in cytokinesis; direct interaction should not be assumed from these data.

### 4. DNA replication module: TIMELESS / FEN1 / TK1 / CCNE2  
- **Direction:** Risk-associated.  
- **Role:** S-phase entry, dNTP production, Okazaki fragment processing, replication fork protection.  
- **Gene-gene relationship:** Pathway co-membership, not necessarily direct physical interaction. Important caveat: RPA2, another DNA-replication-related gene, is protective in this table, so this module is not uniform and may reflect context-dependent effects.

### 5. RNA translation / ribosome biogenesis module: LARP1 / YTHDF1 / UTP23 / DDX41  
- **Direction:** Risk-associated.  
- **Role:** Ribosome production and translation control.  
- **Gene-gene relationship:** Regulatory or pathway relationship, not direct physical interaction. LARP1 and YTHDF1 are both translation regulators; UTP23 and DDX41 are ribosome biogenesis factors.

### 6. Ubiquitin–proteasome module: STIP1 / PSMD3 / UBE2S / USP30 / FAF2  
- **Direction:** Risk-associated.  
- **Role:** Protein folding, ubiquitination, deubiquitination, and proteasomal degradation.  
- **Gene-gene relationship:** Pathway co-membership. STIP1 binds Hsp70/Hsp90 directly, but the relationship among STIP1, PSMD3, USP30, and FAF2 is not a single direct complex.

### 7. Dendritic / plasma / lymphoid immune module: FCER1A / CD1C / CD1E / JCHAIN / KLRB1 / IL27RA / FLT3  
- **Direction:** Protective-associated.  
- **Role:** Markers of dendritic cells, plasma cells, NK/T cells, and immune regulation.  
- **Gene-gene relationship:** Co-expression / cell-type marker relationship, not direct protein interaction. They likely reflect immune cell infiltration.

### 8. Stromal / differentiation module: LAMA2 / COL14A1 / OGN / MFAP4 / ADAMTS8 / TP63 / CDKN2C / SPRY2 / STAT5A / STAT5B  
- **Direction:** Protective-associated.  
- **Role:** ECM organization, epithelial differentiation, and negative regulation of proliferation.  
- **Gene-gene relationship:** Co-expression / pathway co-membership. No single direct physical interaction is implied across this heterogeneous module.

---

## 4. Validation priorities

### 1. Mitotic and APC/C module as a mechanistic driver  
**Classification:** Mechanistic hypothesis  

- **Why prioritize:** It is the strongest and most coherent risk-associated signal.  
- **Current evidence:** Multiple independent mitotic and APC/C genes are risk-associated with very low FDR.  
- **External evidence:** AURKA and CDC20 are known oncogenic regulators in breast cancer and other tumors; TPX2 and APC/C components have established mitotic roles.  
- **Next step:** Perturb AURKA, TPX2, CDC20, or UBE2C in breast cancer models; assess proliferation, aneuploidy, mitotic timing, and tumor growth.  
- **Conclusion:** Supported hypothesis, not yet established as causal from this dataset.

---

### 2. Immune-cell-associated protective signature as a prognostic biomarker  
**Classification:** Biomarker  

- **Why prioritize:** Immune infiltration can be prognostically relevant and potentially immunotherapeutically informative.  
- **Current evidence:** Multiple independent dendritic/plasma/lymphoid markers are protective-associated.  
- **External evidence:** Immune infiltration is associated with better survival in several breast cancer subtypes, although the effect varies by subtype and treatment.  
- **Next step:** Validate in independent breast cancer cohorts with digital cytometry or deconvolution; adjust for subtype, stage, and treatment.  
- **Conclusion:** Supported hypothesis; requires independent validation.

---

### 3. TPX2–AURKA and KIF4A–PRC1 interaction modules in breast cancer  
**Classification:** Interaction / network hypothesis  

- **Why prioritize:** These direct interactions are biologically important in mitosis, but their prognostic relevance in breast cancer is not directly tested here.  
- **Current evidence:** The genes are co-risk in the table, but no interaction evidence is contained in the dataset.  
- **External evidence:** Direct physical interactions are established in non-breast systems.  
- **Next step:** Co-immunoprecipitation, proximity ligation, or CRISPR-based functional rescue in breast cancer cell lines.  
- **Conclusion:** Exploratory for breast cancer prognosis; established as cell biology in other contexts.

---

### 4. Ubiquitin–proteasome/proteostasis program as a therapeutic target  
**Classification:** Therapeutic target hypothesis  

- **Why prioritize:** Proteasome and ubiquitin-pathway genes are consistently risk-associated, and the pathway is druggable.  
- **Current evidence:** PSMD3, UBE2C, UBE2S, STIP1, USP30, and FAF2 are risk-associated.  
- **External evidence:** Proteasome inhibitors are clinically useful in some cancers, but their efficacy in breast cancer is not established. Drug availability alone is not evidence of target validity.  
- **Next step:** Genetic inhibition of PSMD3 or UBE2C in breast cancer models; test dependency, proteotoxic stress, and synergy with standard therapies.  
- **Conclusion:** Exploratory hypothesis.

---

### 5. Cell-composition and tumor-purity confounding check  
**Classification:** Confounding / composition check  

- **Why prioritize:** Many protective genes are lineage markers for immune and stromal cells; risk genes may partly reflect tumor proliferation.  
- **Current evidence:** The protective arm is enriched for immune/ECM markers; the risk arm is enriched for proliferation genes.  
- **External evidence:** Bulk tumor transcriptomes are strongly influenced by cell-type proportions.  
- **Next step:** Use deconvolution methods, single-cell RNA-seq, spatial transcriptomics, or tumor-purity adjustment to determine whether the associations are cell-intrinsic or composition-driven.  
- **Conclusion:** Exploratory; the current associations may be substantially compositional.

---

## 5. Evidence grounding

The interpretation uses several evidence types, and it is important to distinguish them:

- **Direct evidence from the input dataset:** HR, P value, FDR for each gene. This is the only formal statistical evidence.
- **Pathway / ontology evidence:** Based on existing gene-set annotation, not calculated from the input table. It is biologically informative but not independent of prior knowledge.
- **Protein interaction / regulatory evidence:** Known from cell-biology literature, e.g., TPX2–AURKA, PRC1–KIF4A, APC/C–UBE2C. These are independent of the survival statistics but are not directly demonstrated by this dataset.
- **Expression / tissue evidence:** Many protective genes are known cell-lineage markers, e.g., FCER1A/CD1C in dendritic cells, JCHAIN in plasma cells, OGN/MFAP4 in stroma. This supports the idea of cell-composition signals.
- **Disease-association evidence:** External breast cancer literature linking proliferation to poor outcome and immune infiltration to favorable outcome. This is independent but may overlap with the same gene annotations and prior prognostic signatures.
- **Genetic / clinical evidence:** Not provided in this table. Any genetic or clinical causal claims would require additional data.
- **Drug / therapeutic evidence:** Not used as evidence for target validity. Drug existence alone is not sufficient.

Conflicting evidence also exists. For example:

- RPA2 is a DNA-replication gene but is protective in this dataset, unlike the other replication-associated risk genes.
- CCND2 can promote cell-cycle progression in some contexts but is protective here.
- ABCB1 is classically associated with multidrug resistance yet is protective-associated in this table.
- DDX41 has both RNA-processing and innate-immune functions, so its risk signal could reflect more than ribosome biogenesis.

These conflicts argue against forcing every gene into a single pathway label.

---

## 6. Limitations and alternative explanations

### 1. Bulk tissue composition and tumor purity  
Breast tumor tissue contains cancer cells, immune cells, fibroblasts, endothelial cells, and adipocytes. Protective genes such as FCER1A, CD1C, JCHAIN, LAMA2, and OGN likely reflect the cellular composition of the tissue rather than tumor-cell-intrinsic biology. Risk genes such as AURKA, CDC20, and TK1 may reflect tumor proliferation and therefore tumor content/grade. This can be tested by deconvolution, single-cell RNA-seq, spatial transcriptomics, or adjusting for tumor purity.

### 2. Missing clinical covariates  
The table does not show whether the hazard ratios are adjusted for age, stage, grade, molecular subtype, or treatment. In breast cancer, OS is strongly influenced by these variables. The observed associations could be confounded by subtype—for example, luminal A tumors are less proliferative and more differentiated, while basal-like tumors are more proliferative and have different immune/stromal microenvironments. Multivariate Cox models and subtype-stratified analyses are needed.

### 3. Modest effect sizes and context dependency  
Most HRs are between roughly 0.79 and 1.26. Even with very small FDRs, individual-gene effects are modest. The biological importance of a gene cannot be inferred from HR magnitude alone, and context-dependent functions may invert expected directions.

### 4. Gene pleiotropy and pathway overlap  
Several genes belong to multiple biological programs. For example, UBE2C and UBE2S are both mitotic and proteasomal; CDC20 is involved in both cell-cycle and ubiquitination; DDX41 is involved in both RNA processing and innate immunity. This overlap means that pathway labels are approximate, and formal gene-set enrichment would be needed to quantify enrichment rather than relying on manual grouping.

### 5. Unknown methodological details  
No information is given about cohort size, platform, normalization, survival model, gene selection, or whether the FDR correction was genome-wide. Batch effects, sample selection, and model specifications can affect HR estimates and FDRs. Independent validation in external cohorts is therefore essential before any clinical or mechanistic conclusion.

---

Overall, the data support a coherent model in which **high expression of proliferation and protein-production machinery is associated with worse overall survival**, while **the presence of immune and stromal/differentiation-related transcripts is associated with better overall survival**. The strongest biological interpretation is that the risk arm reflects tumor-cell proliferation and growth capacity, whereas the protective arm reflects immune infiltration and a less aggressive, more differentiated microenvironment. However, these are associations, and the causal or cell-intrinsic nature of these signals remains to be established.
